API Purification - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

API Purification
Pharmaceutical Technology Europe speaks to Peter Koklitis, a technical filtration specialist at 3M's purification division, about the latest trends, techniques and technologies in API purification.


Pharmaceutical Technology Europe
Volume 23, Issue 9

How has the trend towards single-use technologies impacted API filtration processes?

As mentioned previously, there has been much innovation in the area of single-use systems. However, although such systems are being used in API filtration, particularly in API bioprocessing, disposable solutions do not necessarily suit all situations. The investment and maintenance costs of all process steps need to be calculated and then considered for both disposable and stainless steel systems. The calculations that contribute to forming a decision should include workers time, water, cleaning chemicals and waste disposal costs. The adoption of plastic encapsulated filters is also restricted when chemically aggressive solvents are used. Future process design technologies may yield novel reaction pathways, which use less challenging solvent systems, and such advances would contribute to widening the adoption of single-use components.

Single-use systems are also being used for highly potent APIs. These ingredients require special containment, but a range of solutions have been developed in this area, such as encapsulated filter media that can clarify harvests.

What are the latest trends in API filtration equipment/services?

Bioprocessing companies are achieving higher titres for their target API proteins, typically monoclonal antibody fragments. A consequence of this is to allow smaller bioreactors to be used with smaller facility design specifications in order to obtain the required amounts of product for clinical trials. These smaller throughput requirements have contributed to the increased use of single-use technologies for the purification process, as well as for the bioreactor. Consequently, demand has grown for single-use sterile connectors, membrane-chromatographic adsorbers, sensors and mixers, as well as production-scale filter capsules, containers and the bioreactors themselves. The standardisation of all these single-use components, with respect to materials and dimensions of connectors and fittings, is a user consideration. However, many of the design features and materials of these components will remain proprietary to specific manufacturers.

Peter Koklitis is a technical filtration specialist at 3M's Purification Division.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology Europe,
Click here